What is Oxitec?
Oxitec is a biotechnology leader specializing in the development of self-limiting insect technology designed to combat invasive, disease-spreading species such as Aedes aegypti. By engineering male mosquitoes that do not bite and do not persist in the environment, the company provides a targeted, environmentally conscious method for population suppression. This innovation eliminates the need for traditional adult mosquito-rearing and release programs, significantly reducing operational costs while maintaining high efficacy rates. Recent field trials, including those in Brazil, have validated the technology's ability to suppress disease-carrying populations by up to 95% in dengue-prone urban settings, positioning Oxitec as a critical player in global public health infrastructure.
How much funding has Oxitec raised?
Oxitec has raised a total of $35.2M across 5 funding rounds:
Private Equity
$2.6M
Private Equity
$3M
Private Equity
$12.6M
Private Equity
$10.2M
Private Equity
$6.8M
Private Equity (2005): $2.6M with participation from East Hill Management Company, LLC, Oxford Capital Partners, and Oxford University
Private Equity (2007): $3M led by East Hill Management Company, LLC and Oxford Capital Partners
Private Equity (2012): $12.6M supported by Asia Pacific Capital and Oxford Capital Partners
Private Equity (2014): $10.2M featuring East Hill Management, Oxford Capital Partners, and Oxford University
Private Equity (2021): $6.8M backed by The Wellcome Trust
Key Investors in Oxitec
The Wellcome Trust
An independent global charitable foundation based in London that supports discovery research and tackles urgent health challenges through grants, partnerships, and advocacy.
Oxford Capital Partners
An investment manager based in the UK that provides growth capital to smaller companies across various industries to help entrepreneurs scale their businesses.
East Hill Management
A Boston-based investment advisory firm focused on managing alternative assets and supporting early-stage companies spun out of academic institutions.
What's next for Oxitec?
Looking ahead, Oxitec is well-positioned to scale its operations globally, leveraging its recent strategic financing to expand into new geographies and address emerging vector-borne health threats. The company's focus remains on refining its biological control platform to ensure seamless integration with existing public health initiatives. As it moves into this next phase of commercialization, Oxitec will likely prioritize regulatory approvals and strategic partnerships with governmental health agencies. The continued support from institutional investors and charitable foundations provides the necessary runway to optimize its cost-efficient, high-impact solutions, ultimately aiming to redefine the standard of care for vector control on a global scale.
See full Oxitec company page
